PTC Therapeutics
PTCT
239 hedge funds and large institutions have $3.51B invested in PTC Therapeutics in 2024 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 78 increasing their positions, 77 reducing their positions, and 17 closing their positions.
229% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 17
20% more capital invested
Capital invested by funds: $2.93B → $3.51B (+$583M)
18% more funds holding
Funds holding: 202 → 239 (+37)
1% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 77
1.69% less ownership
Funds ownership: 102.46% → 100.76% (-1.7%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
62% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $28.2M
Top Buyers
Top Sellers
PTCT Hedge Fund Activity: Q4 2024 in Review
239 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2024, worth a combined $3.51B — up 20% from $2.93B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new PTCT positions and 17 closed out — a net gain of 39 holders — while 78 added to existing stakes and 77 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $141M. The largest seller was Wellington Management Group, cutting an estimated $133M.
- 239 institutional investors held PTC Therapeutics (PTCT) as of Q4 2024, up from 202 in Q3 2024.
- Funds reported $3.51B of PTC Therapeutics stock for Q4 2024, up 20% quarter-over-quarter.
- 56 funds opened new PTC Therapeutics positions in Q4 2024 and 17 closed out, a net change of +39 holders.
- The largest PTC Therapeutics buyer in Q4 2024 was Toronto Dominion Bank, an estimated $141M added.
- The largest PTC Therapeutics seller in Q4 2024 was Wellington Management Group, an estimated $133M sold.
Based on aggregated 13F filings for Q4 2024.